Writing in a recent issue of Nature, Dr. Benjamin Haibe-Kains of the Institut de Recherches Cliniques de Montréal says that additional standardization to improve the reproducibility of drug screening studies is needed.
In the 13 years since the publication of the rough draft of the human genetic code, scientists have run thousands of genome-wide association studies to find links between DNA and disease. The work has delivered some insights, but also shown the method has limitations. Now, a new approach could avoid these flaws.
Three of the industry's leading discovery-stage venture groups have come up with a $43 million commitment to back a crew of marquee thinkers in the genomics field to launch Editas Medicine, a biotech exploratory vehicle that will set out to pioneer a new field of drug development.
Open and closed systems have divided the tech sector for years, with people taking deeply entrenched positions in Apple versus Android and Linux versus Windows debates. And when this philosophical split is applied to genomics, the stakes ratchet up significantly, as the U.K. found this week.
Open-source software developers have long stood on the shoulders of giants, incorporating existing tools where possible so they can focus resources on improving other areas. And with the proliferation of open-source genomics programs, Biodatomics is betting on the model working for bioinformatics.
Narges Bani Asadi, founder and CEO of Bina Technologies By Narges Bani Asadi One of the elements lacking in the personalized medicine discussion today is the perspective of clinicians and...
The sequencing world congregated in Boston last week for the American Society of Human Genetics. At the show, Oxford Nanopore gave attendees a look at the latest iteration of its handheld MinION sequencer and revealed when and how researchers can finally get their hands on the device.
Arch and Polaris have founded NextCODE Health in a $15 million Series A round and inked a five-year exclusive license for the genomics platform developed by deCode.
When Google unveiled its antiaging venture Calico, it gave very few details about the nuts and bolts of the company. Now, reports on the questions Calico will look into--and how much cash it will have to answer them--have started to emerge.
In December Prime Minister David Cameron outlined his plan to turn the United Kingdom into a world-leader in medical genomics, but beyond the headline grabbing numbers--$160 million to sequence 100,000 whole genomes--details were scarce. Now, the group tasked with the project has spoken up.